Summit Place Financial Advisors LLC lowered its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 2.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 26,413 shares of the healthcare product maker’s stock after selling 705 shares during the quarter. Abbott Laboratories comprises approximately 1.7% of Summit Place Financial Advisors LLC’s holdings, making the stock its 29th largest holding. Summit Place Financial Advisors LLC’s holdings in Abbott Laboratories were worth $3,011,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. LVW Advisors LLC lifted its stake in shares of Abbott Laboratories by 8.2% during the 1st quarter. LVW Advisors LLC now owns 6,016 shares of the healthcare product maker’s stock worth $684,000 after purchasing an additional 455 shares during the last quarter. Claro Advisors LLC lifted its position in shares of Abbott Laboratories by 3.6% during the first quarter. Claro Advisors LLC now owns 8,544 shares of the healthcare product maker’s stock valued at $971,000 after buying an additional 297 shares during the last quarter. Synergy Asset Management LLC boosted its holdings in shares of Abbott Laboratories by 37.2% in the 1st quarter. Synergy Asset Management LLC now owns 42,054 shares of the healthcare product maker’s stock valued at $4,780,000 after buying an additional 11,392 shares in the last quarter. Dash Acquisitions Inc. raised its stake in shares of Abbott Laboratories by 3.7% during the 1st quarter. Dash Acquisitions Inc. now owns 102,879 shares of the healthcare product maker’s stock worth $10,895,000 after acquiring an additional 3,689 shares in the last quarter. Finally, Buffington Mohr McNeal lifted its position in Abbott Laboratories by 1.9% during the first quarter. Buffington Mohr McNeal now owns 93,234 shares of the healthcare product maker’s stock valued at $10,597,000 after acquiring an additional 1,695 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In related news, CEO Robert B. Ford sold 141,679 shares of Abbott Laboratories stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $116.41, for a total value of $16,492,852.39. Following the completion of the transaction, the chief executive officer now owns 220,059 shares in the company, valued at $25,617,068.19. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.10% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on ABT
Abbott Laboratories Stock Performance
NYSE ABT opened at $114.22 on Monday. Abbott Laboratories has a fifty-two week low of $91.64 and a fifty-two week high of $121.64. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.68. The firm has a market capitalization of $198.70 billion, a P/E ratio of 35.58, a PEG ratio of 2.74 and a beta of 0.72. The stock has a 50-day simple moving average of $114.63 and a two-hundred day simple moving average of $108.66.
Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.01. The company had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $10.55 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%. Abbott Laboratories’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.14 earnings per share. On average, equities analysts forecast that Abbott Laboratories will post 4.66 earnings per share for the current year.
Abbott Laboratories Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be issued a $0.55 dividend. The ex-dividend date of this dividend is Tuesday, October 15th. This represents a $2.20 dividend on an annualized basis and a yield of 1.93%. Abbott Laboratories’s payout ratio is 68.54%.
Abbott Laboratories Profile
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Further Reading
- Five stocks we like better than Abbott Laboratories
- How to Capture the Benefits of Dividend Increases
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
- Consumer Staples Stocks, Explained
- Alphabet’s Earnings Could Surprise—Should You Buy Now?
- What Do S&P 500 Stocks Tell Investors About the Market?
- MaxLinear: Staging a Turnaround for the AI Broadband Chip Maker
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.